buyWeak
Silver Point Capital L.P. bought $27M of Keenova Therapeutics plc
owner at Keenova Therapeutics plc. 290,000 shares at an average of $93.75, traded Nov 10, 2025, filed Nov 12, 2025.
Conviction score
35Value
$27M
290,000 shares
Holdings after
4,503,724
+7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +12Role10% owner
- +25Trade size$27.2M at market
- +3Relative to holdingsHoldings up 7%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001193125-25-278319, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 10, 2025 | POpen-market purchase Common Stock | +290,000 | $93.75 | $27M | 4,503,724 | Nov 12, 2025 |
Related signals
Other insiders at Keenova Therapeutics plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | -buy Keenova Therapeutics plc | Goldentree Asset Management LP owner | $42M 463,000 shares | +6% | |
| 40Moderate | -buy Keenova Therapeutics plc | Silver Point Capital L.P. owner | $23M 250,000 shares | +5% | |
| 37Weak | -buy Keenova Therapeutics plc | Silver Point Capital L.P. owner | $12M 130,974 shares | +3% | |
| 37Weak | -buy Keenova Therapeutics plc | Silver Point Capital L.P. owner | $6.0M 68,000 shares | +2% | |
| 32Weak | -buy Keenova Therapeutics plc | Goldentree Asset Management LP owner | $3.2M 36,700 shares | +0% | |
| 27Weak | -buy Keenova Therapeutics plc | Goldentree Asset Management LP owner | $4.3M 50,000 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.